Targeted radionuclide therapy: Proceedings of a joint workshop hosted by the National Cancer Institute and the society of nuclear medicine and molecular imaging

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 337-348

  Fahey, Frederic ^a,b   Zukotynski, Katherine ^b,c   Capala, Jacek ^d   Knight, Nancy ^e  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOISOTOPE;

BONE DISEASE; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; HISTORY OF MEDICINE; HUMAN; LYMPHOMA; MEDICAL EDUCATION; MEDICAL ONCOLOGIST; MEDICAL RESEARCH; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; TARGETED RADIONUCLIDE THERAPY; METHODOLOGY; MOLECULAR IMAGING; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NUCLEAR PHYSICS; RADIOCHEMISTRY; UNITED STATES;

HUMANS; MARYLAND; MOLECULAR IMAGING; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; NUCLEAR MEDICINE; NUCLEAR PHYSICS; RADIOCHEMISTRY; RADIOISOTOPES; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84897958983     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.135178     Document Type: Conference Paper

References (132)

1. Joint NCI/SNMMI Workshop on Targeted Radionuclide Therapy. J Nucl Med. 2013;54(5): 16N-17N.
2. Sgouros G, Roeske JC, McDevitt MR, et al. MIRD pamphlet no. 22: radiobiology and dosimetry of a-particle emitters for targeted radionuclide therapy. http://interactive.snm.org/docs/MIRD-Alpha-paper-Mar%2011-09-Jun%2019- 09.pdf. Accessed November 19, 2013.
3. Bell AG. The uses of radium. Am Med. 1903;6: 261-266.
4. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 1946; 132: 838-847.
5. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J Clin Invest. 1983;72: 2101-2114.
6. Jurcic JG, McDevitt MR, Sgouros G, et al. Targeted alpha-particle therapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33) [abstract]. Blood. 1997;90: 2245.
7. Harrison MR, Wong TZ, Armstrong AJ, George DJ. Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res. 2013;5: 1-14.
8. Perkins A. In vivo molecular targeted radiotherapy. Biomed Imaging Interv J. 2005;1: e9.
9. Sgouros G, Barest G, Thekkumthala J, et al. Treatment planning for internal radionuclide therapy: three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med. 1990;31: 1884-1891.
10. Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med. 2007;48: 1008-1016.
11. Kolbert KS, Sgouros G, Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997;38: 301-308.
12. Baechler S, Hobbs RF, Prideaux AR, Wahl RL, Sgouros G. Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry. Med Phys. 2008;35: 1123-1134.
13. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(suppl 1): 99S-106S.
14. Hobbs RF, Sgouros G. Calculation of the biological effective dose for piecewise defined dose-rate fits. Med Phys. 2009;36: 904-907.
15. 124I-PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-Time treatment planning and methodologic comparison. J Nucl Med. 2009;50: 1844-1847.
16. Hobbs RF, McNutt T, Baechler S, et al. A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy. Int J Radiat Oncol Biol Phys. 2011;80: 1256-1262.
17. Watchman CJ, Jokisch DW, Patton PW, Rajon DA, Sgouros G, Bolch WE. Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male. J Nucl Med. 2005;46: 1171-1185.
18. 213Bi (alpha-emitter)-Antibody targeting of breast cancer metastases in the neu-N transgenic mouse model. Cancer Res. 2008;68: 3873-3880.
19. Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol. 2007;19: 308-314.
20. Akabani G, Carlin S,Welsh P, Zalutsky MR. In vitro cytotoxicity of 211At-labeled trastuzumab in human breast cancer cell lines: effect of specific activity and HER2 receptor heterogeneity on survival fraction. Nucl Med Biol. 2006;33: 333-347.
21. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366: 1663-1673.
22. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013;368: 623-632.
23. Seldin DW. Techniques for using Bexxar for the treatment of non-Hodgkin's lymphoma. J Nucl Med Technol. 2002;30: 109-114.
24. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125: 1678-1685.
25. Kaminski MS, Radford JA, Gregory SA, et al. Re-Treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23: 7985-7993.
26. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352: 441-449.
27. Leahy MF, Seymour JF, Hicks RJ, Turner JH. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol. 2006;24: 4418-4425.
28. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24: 4143-4149.
29. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002;20: 2453-2463.
30. 90Yttrium- ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013;31: 1977-1983.
31. He B, Wahl RL, Sgouros G, et al. Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning: patient studies. Med Phys. 2009;36: 1595-1601.
32. Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-Targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40: 173-185.
33. Matthay KK, Tan JC, Villablanca JG, et al. Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a New Approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol. 2006;24: 500-506.
34. 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. J Nucl Med. 2012;53: 1155-1163.
35. Schaefer NG, Ma J, Huang P, Buchanan J, Wahl RL. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med. 2010;51: 987-994.
36. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle cell lymphomas: an open-label, multicenter, randomized, phase 3 noninferiority trial. Lancet. 2013;381: 1203-1210.
37. Martinelli G, Schmitz SF, Utiger U, et al. Long-Term follow-up of patients with follicular lymphoma receiving single-Agent rituximab at 2 different schedules in trial SAKK 37/98. J Clin Oncol. 2010;28: 4480-4484.
38. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377: 42-51.
39. Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results. Paper presented at: 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, LA. https://ash. confex.com/ash/2009/webprogram/Paper24876.html. Updated December 3, 2009. Accessed November 19, 2013.
40. Ardeshna KM, QianW, Smith P, et al. An intergroup randomized trial of rituximab versus a watch and wait strategy in patients with stage II, II, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): a preliminary analysis [abstract]. Blood. 2010; 115: 6.
41. Ardeshna KM, Smith P, Norton A, et al. Long-Term effect of a watch and wait policy versus immediate treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomized controlled trial. Lancet. 2003;362: 516-522.
42. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer. 2010;116: 106-114.
43. Press OW, Unger JM, Rimza L, et al. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-Tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. 2013;31: 314-320.
44. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26: 5156-5164.
45. Morschhauser F, Illidge T, Huglo D, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110: 54-58.
46. Hamlin PA, Rodriguez MA, Nov A, et al. Final results of a phase II study of sequential R-CHOP and yttrim-90 ibritumomab tiuxetan (RIT) for elderly high risk patients with untreated diffuse large B-cell lymphoma (DLBCL) [abstract]. Blood. 2010;116: abstract 1793.
47. Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMY CTN 0401 trial. J Clin Oncol. 2013;31: 1662-1668.
48. Smith MRLH, Gordon L, Gascoyne RD, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30: 3119-3126.
49. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012;367: 520-531.
50. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321: 419-424.
51. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351: 1502-1512.
52. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14: 1756-1764.
53. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med. 1984;311: 1281-1286.
54. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94: 1458-1468.
55. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351: 1513-1520.
56. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364: 1995-2005.
57. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011;377: 813-822.
58. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367: 1187-1197.
59. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363: 411-422.
60. Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20(suppl 2): 45-54.
61. Tu SM, Millikan RE, Mengistu B, et al. Bone-Targeted therapy for advanced androgen-dependent carcinoma of the prostate: a randomized phase II trial. Lancet. 2001;357: 336-341.
62. Parker C, Nilsson S, Heinrich, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369: 213-223.
63. 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(suppl): 6250s-6257s.
64. Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008;38: 358-366.
65. 131I-metaiodobenzylguanidine. J Nucl Med. 1980;21: 349-353.
66. 131I]metaiodobenzylguanidine: results from 10 years experience. J Nucl Biol Med. 1991;35: 269-276.
67. 131I- metaiodobenzylguanidine. J Nucl Biol Med. 1991;35: 292-294.
68. 131I-metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma. J Nucl Biol Med. 1991;35: 288-291.
69. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic, and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest. 1992;15: 631-642.
70. 131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma. J Nucl Biol Med. 1991;35: 277-279.
71. 131I-metaiodobenzylguanidine: a French multicenter study. J Nucl Biol Med. 1991;35: 284-287.
72. 131I- iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 1991;72: 455-461.
73. Shilkrut M, Bar-Deroma R, Bar-Sela G, Berniger A, Kuten A. Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with pheochromocytoma and paraganglioma: single center experience. Ann J Clin Oncol. 2010;33: 79-82.
74. 131I-metaiodiobenzylguanidine. CA Cancer J Clin. 1984;34: 86-92.
75. Sisson JC, Shapiro B, Beierwaltes WH, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med. 1984;25: 197-206.
76. 131I-MIBG as an aid to the treatment of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Henry Ford Hosp Med J. 1984;32: 254-261.
77. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest. 1997;20: 648-658.
78. 131I-meta-iodobenzylguanidine. Clin Endocrinol (Oxf). 2001;55: 46-60.
79. 131I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging. 2010;54: 100-113.
80. Hartley A, Spooner D, Brunt AM. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol (R Coll Radiol). 2001;13: 361-366.
81. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008; 35: 725-733.
82. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodiobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery. 2003;134: 956-962.
83. 131I-MIBG therapy. Clin Oncol (R Coll Radiol). 2003;15: 193-198.
84. 131I- metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer. 2003;98: 239-248.
85. 131Imetaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27: 4162-4168.
86. Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27: 273-282.
87. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30: 917-920.
88. 90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006; 36: 147-156.
89. Nguyen C, Faraggi M, Giraudet AL, et al. Long-Term efficacy of radionuclide therapy with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med. 2004;45: 1660-1668.
90. 90Y-DOTA-D- Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers. 2002;66: 393-398.
91. de Jong M, Breeman WA, Kwekkeboom DJ, Valkema R, Krenning EP. Tumor imaging and therapy using radiolabeled somatostatin analogues. Acc Chem Res. 2009;42: 873-880.
92. 177Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2010;51: 383-390.
93. 90Y-DOTATOC. J Nucl Med. 2002;43: 610-616.
94. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12: 941-945.
95. Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52: 334-340.
96. 90Y-DOTATOC. J Nucl Med. 2005;46: 1310-1316.
97. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26: 1439-1447.
98. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34: 1617-1626.
99. 68Ga-DOTATOC PET/CT examinations [in German]. Nuklearmedizin. 2009;48: 201-207.
100. 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53: 1207-1215.
101. 86Y-DOTA0)-D-Phe1-Tyr3- octreotide (SMT487): a phase 1 clinical study -pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30: 510-518.
102. 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16: 2899-2905.
103. Kratochwil C, Lopez-Benitez R, Mier W, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patient with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18: 595-602.
104. Bass RT, Buckwalter BL, Patek BP, et al. Identification and characterization of novel somatostatin antagonists. Mol Pharmacol. 1996;50: 709-715.
105. Cescato R, Erchegyi K, Waser B, et al. Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotherapy. J Med Chem. 2008;51: 4030-4037.
106. 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. J Nucl Med. 2011;52: 1886-1890.
107. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52: 1412-1417.
108. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector, 1,4,7,10-Tetraazacyclododecane-1-glutaric acid-4,7,10-Triacetic acid-substance p. Clin Cancer Res. 2006;12: 3843-3850.
109. 131I-3F8. J Clin Oncol. 2007;25: 5465-5470.
110. 90Y. Cancer Res. 2009;69: 8941-8948.
111. Dumont RA, Tamma M, Braun F, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as a monotherapy and in combination with rapamycin. J Nucl Med. 2013;54: 762-769.
112. Gornik G, Mansi R, Abiraj K, et al. Evaluation of the GRPR radioantagonist Cu-64-CB-TE2A-AR-06 in mice and men [abstract]. J Nucl Med. 2011;52(suppl): 7P
113. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487: 330-337.
114. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490: 61-70.
115. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012;489: 519-525.
116. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-892.
117. 90Y-DOTATOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29: 2416-2423.
118. 177Lu-DOTA 0,Tyr 3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26: 2124-2130.
119. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26: 3063-3072.
120. 177Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30: 1100-1106.
121. Kulke MH, Siu LL, Tepper JE, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol. 2011;29: 934-943.
122. Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecker HR. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39: 1876-1885.
123. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2): 42S-55S.
124. Barbet J, Chatal JF, Gauche F, Martino J. Which radionuclides will nuclear oncology need tomorrow? Eur J Nucl Med Mol Imaging. 2006;33: 627-630.
125. Delbeke D, Segall HM. Status and trends in nuclear medicine in the US. J Nucl Med. 2011;52(suppl 2): 24S-28S.
126. Dondi M, Kashyap R, Paez D, et al. Trends in nuclear medicine in developing countries. J Nucl Med. 2011;52(suppl 2): 16S-23S.
127. Graham MM, Menda Y. Radiopeptide imaging and therapy in the US. J Nucl Med. 2011;52(suppl 2): 56S-63S.
128. Josephson L, Rudin M. Barriers to clinical translation with diagnostic drugs. J Nucl Med. 2013;54: 329-332.
129. Schelbert HR. Nuclear medicine at a crossroads. J Nucl Med. 2011;52(suppl 2): 10S-15S.
130. Schwaiger M, Wester HJ. How many PET tracers do we need? J Nucl Med. 2011;52(suppl 2): 36S-41S.
131. Zimmermann RG. Industrial constraints in the selection of radionuclides and the development of new radiopharmaceuticals. World J Nucl Med. 2008;7: 126-134.
132. Zimmermann RG. Why are investors not interested in my radiotracer? The industrial and regulatory constraints in the development of radiopharmaceuticals. Nucl Med Biol. 2013;40: 155-166.